

4th March, 2017

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> |
|---|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg


Dear Sirs,

We are enclosing herewith the Press Release on divestment of animal health business of the Company in South Africa and Sub-Saharan Africa.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure - I.

Thank you,

For Cipla Limited



Rajendra Chopra
Company Secretary

Encls:

1. Press Release on divestment of animal health business
2. Details as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Press Release

Cipla agrees to divest its animal health business in South Africa and Sub-Saharan Africa

Mumbai, March 4, 2017: Cipla Ltd (“Cipla”), a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has entered into agreements, through its Wholly Owned Subsidiary Inyanga Trading 386 Proprietary Limited (“Inyanga”), with the group companies of Ascendis Health Limited, South Africa for divesting its animal health business in South Africa and Sub-Saharan Africa.

Under the Agreements, Cipla will divest its 100% stake in Cipla Agrimed Proprietary Limited (“Cipla Agrimed”), South Africa and Cipla Vet Proprietary Limited (“Cipla Vet”), South Africa. The total consideration of transaction would be ZAR 375 million with potential revision linked to FY2017 performance along with customary adjustment (within the price band of R250m and R500m) in relation working capital and net debt/cash adjustments. The deal is subject to customary closing conditions including approval from competition commission of South Africa and is expected to close in the next 3 months.

Commenting on the development **Paul Miller, CEO, Cipla South Africa** said, “Cipla has taken the strategic decision to divest and sell its veterinary division. In line with this new strategy, the company will increase its focus and efforts to advancing health care for all South Africans. By doing this, Cipla will have a more intensive approach to grow our portfolio of quality and affordable products, with an aim to provide an even broader range of pharmaceutical solutions in more therapeutic areas in the South African Healthcare sector.”

Ascendis Health Limited is a South Africa based health and care brands company operating in human, plant and animal health. “We have full confidence in Ascendis Health’s ability to take both veterinary units to new heights,” says Miller.

Cipla Agrimed operates in the farm animals segment, with sales mainly attributable to agricultural co-operatives and bulk farm purchasing organizations. Cipla Agrimed has a leading position in antimicrobials and endectocides in South Africa.

Cipla Vet operates in the companion animal segment with sales primarily to wholesalers. Cipla Vet has a strong presence in the South African market, with leading positions in Proton Pump Inhibitors, Non-steroidal Anti-inflammatory Drugs (NSAIDs) and supplements.

About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:

Corporate Communications

Pallavi Golar

E Mail: pallavi.golar@cipla.com

Investor Relations

Alpesh Dalal

E-Mail: Investor.Relations@cipla.com

Annexure – I

Sr. No.	Particulars	Details	
		Cipla Vet Proprietary Ltd	Cipla Agrimed Proprietary Ltd
1.	The amount and percentage of the revenue contributed by such unit or division of the listed entity during the last financial year ended 31 st March 2016	~ZAR 48m ~0.16%	~ZAR 201mn ~0.65%
2.	The amount and percentage of net worth contributed by such unit or division of the listed entity during the last financial year ended 31 st March 2016	~ZAR 85mn* ~0.32%	~ZAR 99mn ~0.38%
3.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Klub M5 Proprietary Limited	Afrikelp Proprietary Limited
		<p>Klub M5 Proprietary Limited and Afrikelp Proprietary Limited are group companies of Ascendis Health Limited, South Africa (“Ascendis”)</p> <p>Ascendis is a South Africa based health and care brands company operating in human, plant and animal health.</p> <p>Ascendis’ strategy is to create a synergistic group of health product brands that cover the value chain from imports of raw materials, manufacturing and distribution to consumers via retail and direct selling channels.</p> <p>Ascendis is listed on the Johannesburg Stock Exchange. Ascendis’ largest shareholder is Coast2Coast Capital.</p> <p>The buyers do not belong to the promoter/promoter group/group companies and are not part of any persons acting in concert [PAC] with the promoters.</p>	
4.	Date on which the agreement for sale has been entered	4 th March 2017	
5.	The expected date of completion of sale/disposal	The transaction is expected to be closed in next 3 months subject to completion of certain conditions precedent and regulatory approvals approval from competition commission of South Africa.	



6.	Consideration received from such sale/disposal	Total consideration of ZAR 375 million with potential revision linked to FY 2017 performance along with customary adjustment (within the price band of ZAR 250 m and ZAR 500 m) in relation working capital and net debt/cash adjustments.
7.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	The transaction is not a related party transaction for the Company and has been completed on an arm's length basis.

